ClinicalTrials.gg
CompletedNCT04057937Updated Jul 17, 2024Results posted

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

A Phase 2 interventional study of Apremilast and Placebo in Palmoplantaris Pustulosis, sponsored by Amgen. Completed at 22 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
24th of 44
90 · median 103
Started
2019
with 5 others
Phase 2
10 of 44
none open now
Registered
31st of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 24th largest by enrollment, is one of 6 that started in 2019, is one of 10 in phase 2, and was the 31st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP. This study also will evaluate the safety and tolerability of apremilast in Japanese subjects with PPP.CC-10004-PPP-001 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2 study of apremilast in Japanese subjects with PPP and inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations.

The placebo-controlled period will be 16 weeks and patients will receive apremilast or placebo. After the 16-week placebo-controlled period, all subjects will receive apremilast for 16 weeks. All subjects will have their final study visit 4 weeks after stopping apremilast treatment.

03

Conditions studied

  • Palmoplantaris Pustulosis

Browse trials for

Keywords

  • Palmoplantar Pustulosis
  • CC-10004
  • Apremilast
  • Only Japanese
  • Efficacy
  • Safety
  • Phase 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject has a diagnosis of Palmoplantar Pustulosis with or without pustulotic arthro-osteitis (PAO) for at least 24 weeks before screening.
  2. Subject has a total score of PPPASI: ≥ 12 at screening and baseline.
  3. Subject has moderate or severe pustules/vesicles on palms or soles (PPPASI severity score: ≥ 2) at screening and baseline.
  4. Subject has inadequate response to treatment with topical and/or topical vitamin D3 derivative preparations prior to or at screening.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has a diagnosis of plaque-type psoriasis.
  2. Subject has the presence of pustular psoriasis in any part of the body other than the palms and soles.
  3. Subject has obvious improvement during screening (≥ 5 PPPASI total score improvement during the screening).
  4. Subject has received any procedures for focal infection (e.g, tonsillectomy and dental therapy) within 24 weeks of baseline.
  5. Subject has periodontitis obviously requiring treatment at screening.
  6. Subject has chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment for a month or more at screening.
  7. Subject has evidence of skin conditions of hands and feet that would interfere with evaluations of the effect of study medication.
  8. Subject is pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Placebo then Apremilast 30mg BID

    Participants received matched placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).

    Drug: Apremilast · Drug: Placebo

  • Experimental
    Apremilast 30 mg BID then Apremilast 30 mg BID

    Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).

    Drug: Apremilast

Interventions

  • Apremilast

    Also known as: CC-10004

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve a PPPASI-50 at Week 16

    PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.

    Time frame: At Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieve a PPPASI-50 at All Other Visits in Placebo-controlled Phase

    PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values at were imputed using non-responder imputation (NRI) as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

    Time frame: Weeks 2 to 14

  2. Percentage of Participants Who Achieve a PPPASI-75 at Each Visit in Placebo-controlled Phase

    PPPASI-75 is defined as \>=75 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

    Time frame: Weeks 2 to 16

  3. Area Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 16

    The AUC for PPPASI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPPASI is a disease-specific efficacy assessment tool to evaluate 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.

    Time frame: Baseline to Week 16

  4. Percent Change From Baseline in PPPASI Total Score by Visit in Placebo-controlled Phase .

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. A positive change from baseline indicates a worsening of symptoms.

    Time frame: Baseline to Week 16

  5. Change From Baseline in PPPASI Total Score at Week 16

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.

    Time frame: Baseline and Week 16

  6. AUC for PPSI Total Score From Baseline Through Week 16

    The AUC for PPSI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease.

    Time frame: Baseline to Week 16

  7. Percent Change From Baseline in PPSI Total Score by Visit in Placebo-controlled Phase

    PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. A positive change from baseline indicates a worsening of symptoms.

    Time frame: Baseline to Week 16

  8. Change From Baseline in PPSI Total Score at Week 16

    PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.

    Time frame: Baseline and Week 16

  9. Percentage of Participants Achieving a PGA Score of Clear (0) or Minimal (1) by Visit in Placebo-controlled Phase

    The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with a post baseline score of 0 or 1 (responders) are reported. Missing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

    Time frame: Weeks 2 to 16

  10. Percentage of Participants Achieving a PGA Score of 0 or 1 With At Least a 2 Grade Improvement by Visit in Placebo-controlled Phase.

    The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with at least a 2 grade improvement from baseline (stringent responders) are reported. issing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

    Time frame: Weeks 2 to 16

  11. Change From Baseline in Participant VAS Assessment for PPP Symptoms

    Participants assessed the degree of both pruritus itching and skin discomfort/pain as symptoms on hands and feet caused by PPP on a VAS. Each score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch/pain and the right-hand boundary (100) represents itch/pain as severe as can be imagined by participant.

    Time frame: Baseline and Weeks 2,4,6,8,12,16

07

Results

Posted Jan 6, 2022

Participant flow

Japanese participants with palmoplantar pustulosis (PPP) were enrolled at 22 research centers in Japan from October 2019 to June 2021.

Placebo-controlled Phase
Participant flow — Placebo-controlled Phase
MilestonePlacebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BID
Started4446
Completed4146
Not completed30
Withdrew: Adverse event30
Active-treatment Phase
Participant flow — Active-treatment Phase
MilestonePlacebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BID
Started4146
Completed4044
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Pregnancy01
Withdrew: Physician decision01

Outcome measures

PrimaryPercentage of Participants Who Achieve a PPPASI-50 at Week 16

PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.

Time frame:
At Week 16
Reported as:
Number · Percentage of Partcipants
Percentage of Participants Who Achieve a PPPASI-50 at Week 16
Percentage of PartcipantsPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Percentage of Participants Who Achieve a PPPASI-50 at Week 1640.978.3
Statistical analysis
  • Placebo-controlled Phase - Placebo vs Placebo-controlled Phase - Apremilast 30 mg BID · Chi-squared · p = 0.0003 (Two-sided 0.10 significant level) · Percentage difference:apremilast-placebo: 37.4 · 95% CI 18.6 to 56.1Confidence Intervals calculated using the Wald method (normal approximation).
SecondaryPercentage of Participants Who Achieve a PPPASI-50 at All Other Visits in Placebo-controlled Phase

PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values at were imputed using non-responder imputation (NRI) as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

Time frame:
Weeks 2 to 14
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve a PPPASI-50 at All Other Visits in Placebo-controlled Phase
Percentage of ParticipantsPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Week 22.330.4
Week 418.252.2
Week 618.269.6
Week 843.265.2
Week 1034.171.7
Week 1234.169.6
Week 1447.773.9
SecondaryPercentage of Participants Who Achieve a PPPASI-75 at Each Visit in Placebo-controlled Phase

PPPASI-75 is defined as \>=75 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

Time frame:
Weeks 2 to 16
Reported as:
Number · Percentage of Partcipants
Percentage of Participants Who Achieve a PPPASI-75 at Each Visit in Placebo-controlled Phase
Percentage of PartcipantsPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Week 22.32.2
Week 44.510.9
Week 69.121.7
Week 811.419.6
Week 1011.430.4
Week 1213.630.4
Week 1413.637.0
Week 1615.943.5
SecondaryArea Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 16

The AUC for PPPASI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPPASI is a disease-specific efficacy assessment tool to evaluate 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Scores * Day
Area Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 16
Scores * DayPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Area Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 161911.74 (1707.92 to 2115.57)1337.49 (1134.52 to 1540.47)
SecondaryPercent Change From Baseline in PPPASI Total Score by Visit in Placebo-controlled Phase .

PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. A positive change from baseline indicates a worsening of symptoms.

Time frame:
Baseline to Week 16
Reported as:
Mean · Percent Change
Percent Change From Baseline in PPPASI Total Score by Visit in Placebo-controlled Phase .
Percent ChangePlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Week 2-11.09 ± 22.102-36.62 ± 22.816
Week 4-23.82 ± 28.307-48.96 ± 21.973
Week 6-30.15 ± 24.826-55.06 ± 23.164
Week 8-42.41 ± 27.115-57.11 ± 22.710
Week 10-36.52 ± 32.999-60.85 ± 21.792
Week 12-42.30 ± 26.802-61.22 ± 22.787
Week 14-45.00 ± 30.915-63.78 ± 23.952
Week 16-42.35 ± 32.671-64.33 ± 24.345
SecondaryChange From Baseline in PPPASI Total Score at Week 16

PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in PPPASI Total Score at Week 16
Units on a scalePlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Change From Baseline in PPPASI Total Score at Week 16-11.03 ± 1.260-16.48 ± 1.224
SecondaryAUC for PPSI Total Score From Baseline Through Week 16

The AUC for PPSI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Scores * Day
AUC for PPSI Total Score From Baseline Through Week 16
Scores * DayPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
AUC for PPSI Total Score From Baseline Through Week 16725.62 (668.09 to 783.15)564.63 (507.35 to 621.90)
SecondaryPercent Change From Baseline in PPSI Total Score by Visit in Placebo-controlled Phase

PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. A positive change from baseline indicates a worsening of symptoms.

Time frame:
Baseline to Week 16
Reported as:
Mean · Percent Change
Percent Change From Baseline in PPSI Total Score by Visit in Placebo-controlled Phase
Percent ChangePlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Week 2-6.25 ± 19.409-24.70 ± 19.780
Week 4-13.84 ± 25.629-34.58 ± 23.190
Week 6-20.02 ± 20.639-40.50 ± 23.035
Week 8-30.12 ± 29.340-40.76 ± 23.019
Week 10-27.42 ± 29.635-44.22 ± 24.890
Week 12-31.18 ± 27.817-46.47 ± 25.202
Week 14-34.98 ± 28.205-50.16 ± 25.488
Week 16-30.90 ± 25.414-48.96 ± 21.821
SecondaryChange From Baseline in PPSI Total Score at Week 16

PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in PPSI Total Score at Week 16
Units on a scalePlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Change From Baseline in PPSI Total Score at Week 16-2.56 ± 0.303-4.19 ± 0.293
SecondaryPercentage of Participants Achieving a PGA Score of Clear (0) or Minimal (1) by Visit in Placebo-controlled Phase

The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with a post baseline score of 0 or 1 (responders) are reported. Missing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

Time frame:
Weeks 2 to 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a PGA Score of Clear (0) or Minimal (1) by Visit in Placebo-controlled Phase
Percentage of ParticipantsPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Week 20.02.2
Week 42.34.3
Week 62.34.3
Week 89.18.7
Week 109.113.0
Week 129.115.2
Week 149.117.4
Week 164.519.6
SecondaryPercentage of Participants Achieving a PGA Score of 0 or 1 With At Least a 2 Grade Improvement by Visit in Placebo-controlled Phase.

The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with at least a 2 grade improvement from baseline (stringent responders) are reported. issing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

Time frame:
Weeks 2 to 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a PGA Score of 0 or 1 With At Least a 2 Grade Improvement by Visit in Placebo-controlled Phase.
Percentage of ParticipantsPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Week 20.02.2
Week 42.34.3
Week 62.34.3
Week 89.16.5
Week 109.110.9
Week 129.115.2
Week 149.117.4
Week 164.517.4
SecondaryChange From Baseline in Participant VAS Assessment for PPP Symptoms

Participants assessed the degree of both pruritus itching and skin discomfort/pain as symptoms on hands and feet caused by PPP on a VAS. Each score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch/pain and the right-hand boundary (100) represents itch/pain as severe as can be imagined by participant.

Time frame:
Baseline and Weeks 2,4,6,8,12,16
Reported as:
Mean · Units on scale
Change From Baseline in Participant VAS Assessment for PPP Symptoms
Units on scalePlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BID
Itching Week 2-2.4 ± 25.07-25.0 ± 24.42
Itching Week 4-7.9 ± 21.39-22.7 ± 26.36
Itching Week 6-9.3 ± 29.65-22.4 ± 29.37
Itching Week 8-19.0 ± 25.53-24.8 ± 29.38
Itching Week 12-14.9 ± 35.82-28.3 ± 28.55
Itching Week 16-10.5 ± 30.81-26.8 ± 28.65
Discomfort/Pain Week 2-0.7 ± 32.47-20.2 ± 26.73
Discomfort/Pain Week 4-6.9 ± 30.39-21.6 ± 29.21
Discomfort/Pain Week 6-6.7 ± 28.80-22.4 ± 33.16
Discomfort/Pain Week 8-15.5 ± 31.14-22.0 ± 29.02
Discomfort/Pain Week 12-14.1 ± 32.07-27.6 ± 28.14
Discomfort/Pain Week 16-13.5 ± 27.51-25.3 ± 29.51

Adverse events

Collected over Placebo-controlled Phase: Week 0 to Week 16. Active-treatment Phase: After Week 16 to Week 32.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Phase - Placebo0/44 (0%)0/44 (0%)16/44 (36.4%)
Placebo-controlled Phase - Apremilast 30 mg BID0/46 (0%)0/46 (0%)32/46 (69.6%)
Active-treatment Phase - Apremilast 30 mg BID0/87 (0%)3/87 (3.4%)40/87 (46%)
Most frequent serious events
Most frequent serious events
EventPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BIDActive-treatment Phase - Apremilast 30 mg BID
ConstipationGastrointestinal disorders0/440/461/87
VolvulusGastrointestinal disorders0/440/461/87
COVID-19 pneumoniaInfections and infestations0/440/461/87
PeritonitisInfections and infestations0/440/461/87
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo-controlled Phase - PlaceboPlacebo-controlled Phase - Apremilast 30 mg BIDActive-treatment Phase - Apremilast 30 mg BID
DiarrhoeaGastrointestinal disorders6/4412/468/87
Abdominal discomfortGastrointestinal disorders1/447/466/87
NauseaGastrointestinal disorders2/446/463/87
HeadacheNervous system disorders0/446/464/87
EczemaSkin and subcutaneous tissue disorders5/443/463/87
Faeces softGastrointestinal disorders2/445/463/87
NasopharyngitisInfections and infestations2/445/465/87
Dermatitis contactSkin and subcutaneous tissue disorders1/445/465/87
Palmoplantar pustulosisSkin and subcutaneous tissue disorders1/440/468/87
FolliculitisInfections and infestations4/441/463/87

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
Mean54.7 ± 11.6854.9 ± 11.3054.8 ± 11.42
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
Female333669
Male111021
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
Hispanic or Latino000
Not Hispanic or Latino444690
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
American Indian or Alaska Native000
Asian444690
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Palmo-plantar Pustulosis Area and Severity Index (PPPASI) Score
Palmo-plantar Pustulosis Area and Severity Index (PPPASI) Score(Score on a scale)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
Mean24.93 ± 8.91525.03 ± 8.67524.98 ± 8.744
Palmo-plantar Severity Index (PPSI) Total Score
Palmo-plantar Severity Index (PPSI) Total Score(Score on a Scale)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
Mean8.2 ± 1.498.3 ± 1.488.20 ± 1.48
Physician's Global Assessment (PGA) Score for Palms and Soles
Physician's Global Assessment (PGA) Score for Palms and Soles(Participants)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
0 = Clear000
1 = Almost clear/Minimal000
2 = Mild134
3 = Moderate241640
4 = Severe172138
5 = Very severe268
Participants Visual Analogue Scale (VAS) Assessment for PPP Symptoms
Participants Visual Analogue Scale (VAS) Assessment for PPP Symptoms(Score on a Scale)Placebo Then Apremilast 30mg BIDApremilast 30 mg BID Then Apremilast 30 mg BIDTotal
Itching57.0 ± 27.850.3 ± 31.5853.5 ± 29.85
Discomfort/Pain50.3 ± 29.9845.4 ± 31.9247.8 ± 30.93
08

Study locations

22 sites
  • Research Site
    Ichinomiya, Aichi 491-8558, Japan
  • Research Site
    Nagoya, Aichi 467-8602, Japan
  • Research Site
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • Research Site
    Sapporo-shi, Hokkaido 060-0063, Japan
  • Research Site
    Hitachi, Ibaraki 317-0077, Japan
  • Research Site
    Sagamihara-shi, Kanagawa 252-0392, Japan
  • Research Site
    Yokohoma-shi, Kanagawa 221-0825, Japan
  • Research Site
    Yokosuka, Kanagawa 238-8558, Japan
  • Research Site
    Izumo, Shimane 693-8501, Japan
  • Research Site
    Chiyoda-ku, Tokyo 102-8798, Japan
  • Research Site
    Itabashi-ku, Tokyo 173-8606, Japan
  • Research Site
    Itabashi-ku, 173-8610, Japan
  • Research Site
    Kisarazu, 292-8535, Japan
  • Research Site
    Kofu, 400-0027, Japan
  • Research Site
    Minokamo, 505-8503, Japan
  • Research Site
    Nankoku-shi, 783-8505, Japan
  • Research Site
    Osaka, 550-0006, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 161-8521, Japan
  • Research Site
    Shinjyuku-ku, 160-0023, Japan
  • Research Site
    Toon, 791-0295, Japan
  • Research Site
    Tsu, 514-8507, Japan
09

References and documents

Publications

  • Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study. Am J Clin Dermatol. 2023 Sep;24(5):837-847. doi: 10.1007/s40257-023-00788-2. Epub 2023 May 26. Erratum In: Am J Clin Dermatol. 2024 Jan;25(1):165-167. doi: 10.1007/s40257-023-00825-0. PubMed 37233897 ↗
  • Okubo Y, Terui T, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Kimura T, Shimauchi J, Zhang W, Amouzadeh H, Murakami M. Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study. Dermatol Ther (Heidelb). 2024 Jul;14(7):1863-1873. doi: 10.1007/s13555-024-01195-z. Epub 2024 Jun 19. PubMed 38896381 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jan 2021, 15 months.

Results were first posted in Jan 2022, 11 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 15 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2019
First posted
Aug 15, 2019
StartActual
Oct 16, 2019
Primary completionActual
Jan 18, 2021
CompletionActual
Jun 7, 2021
Results first posted
Jan 6, 2022
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04057937
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 15, 2019
Start date
Oct 16, 2019
Primary completion
Jan 18, 2021
Completion
Jun 7, 2021
Results posted
Jan 6, 2022
Last update
Jul 17, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion